Status:
COMPLETED
CONfident Treatment Decisions in Living With Rheumatoid Arthritis
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Pfizer Independent Grants for Learning and Change
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pilot test the novel educational patient-directed intervention to demonstrate the feasibility of the novel educational approaches developed in improving patient's willingness to achieve remission or l...
Detailed Description
Pilot test the novel educational patient-directed intervention to demonstrate the feasibility of the novel educational approaches developed in improving patient's willingness to achieve remission or l...
Eligibility Criteria
Inclusion
- Have a patient-reported diagnosis of RA
- Most recent RAPID3 \> 12 collected in the last 6 months
- Have not changed RA medication in the last 6 months
- Taking medications that are commonly used in RA (e.g. methotrexate, sulfasalazine, hydroxychloroquine (plaquenil), leflunomide (arava), etanercept (enbrel), adalimumab (Humira), tofacitinib (xeljanz), actemra (tocilizumab), sarilumab (Kevzara) , infliximab (remicade), golimumab (Simponi), rituximab (rituxan), abatacept (Orencia), and certolizumab (Cimzia))
Exclusion
- Does not meet inclusion criteria
- Age \< 18
Key Trial Info
Start Date :
March 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT03317756
Start Date
March 7 2018
End Date
September 1 2020
Last Update
September 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294